National Cancer institute, 33/43 Lomonosova Str., Kyiv, 03022, Ukraine.
Bogomolets National Medical University, 13 Tarasa Shevchenka Ave., Kyiv, 01601, Ukraine.
Probl Radiac Med Radiobiol. 2021 Dec;26:554-561. doi: 10.33145/2304-8336-2021-26-554-561.
Endometrial cancer ranks the third place in prevalence among all cancers in Ukraine. The surgicaltreatment and subsequent adjuvant treatment is planned according to the patient's risk group. The choice of radi-ation therapy and the need to add chemotherapy determines the level of recurrence-free survival.
The aim of the study was to analyze the database of treated patients in National Cancer Institute, with Istage endometrial cancer intermediate and high-intermediate group; determination of the most frequent choice ofradiation treatment in accordance with the risk group of patients with a hysterectomy with salpingo-oophorectomyfor further observation and evaluation of diseasefree survival.
Retrospective was analysed 245 patients with high and intermediate risk groups with stageI endometrial cancer. The exclusion criteria were: low-risk patients, stages II-IV and non-endometrioid histologi-cal variant.
According to the analysis, there were 122/245 (49.8 %) patients of high risk group, 123/245 (50.2 %) ofintermediate risk group. High-risk patients underwent external beam therapy and brychytherapy, supplemented bychemotherapy in 5.8 % of cases (7 patients), brachytherapy with external beam therapy was performed in 58.2 % ofcases (71 patients), brachytherapy - in 8.1 % of cases (10 patients), external beam therapy was performed in 27.9 %cases. Intermediate and high-intermediate risk patients were distributed as follows: brachytherapy was performedin 41.5 % of cases (51 patients), brachytherapy with external beam therapy - 54.5 % (67 patients), external beamtherapy was performed in 5 patients.
Brachytherapy is available for patients with intermediate risk endometrial cancer and external beamtherapy with possible addition of brachytherapy is recommended for high-intermediate and high-risk groups, espe-cially in patients with lymphatic vascular involvement. All patients are monitored for further assessment of recur-rence-free survival.
在乌克兰，子宫内膜癌的发病率在所有癌症中排名第三。手术治疗和随后的辅助治疗是根据患者的风险组来计划的。选择放疗以及是否需要添加化疗决定了无复发生存率。
本研究旨在分析国立癌症研究所治疗患者的数据库，这些患者患有 I 期子宫内膜癌中危和高危-中危组；根据接受子宫切除术和双侧附件切除术的患者风险组确定最常见的放疗选择，以便进一步观察和评估无病生存率。
回顾性分析了 245 名患有 I 期子宫内膜癌高危和中危组的患者。排除标准为：低危患者、II-IV 期和非子宫内膜组织学变异。
根据分析，245 名患者中，高危组 122/245（49.8%），中危组 123/245（50.2%）。高危患者接受外照射治疗和近距离治疗，并在 5.8%的病例（7 例）中补充化疗，58.2%的病例（71 例）接受外照射联合近距离治疗，8.1%的病例（10 例）接受近距离治疗，27.9%的病例接受外照射治疗。中危和高危-中危患者的分布如下：近距离治疗 41.5%（51 例），外照射联合近距离治疗 54.5%（67 例），外照射治疗 5 例。
中危子宫内膜癌患者可选择近距离治疗，高危-中危和高危组推荐行外照射联合可能加用近距离治疗，尤其是有淋巴管血管侵犯的患者。所有患者都接受监测，以进一步评估无复发生存率。
